Drug-resistant infections pose a huge global health challenge. This week, we were in Zambia at the ReAct Africa Annual AMR Conference and to meet the ASPIRE programme team, working for better-informed antibiotic prescription decisions. Find out more: t.ly/LcRUQ

We brought together clinicians, researchers and patient advocates to prioritise new treatment approaches for medulloblastoma. For high-risk disease, we focused on tumour ‘drivers’; for lower-risk subtypes, on opportunities for kinder, antibody-based treatments. 🔗https://t.ly/dE8h-

The UK has been at the forefront of many scientific and medical breakthroughs over the past century. So we're proud to be featured in Monarchy and Democracy: A History of Leadership, which showcases organisations that have contributed to leadership and progress in the UK.

Rare disease affects millions of people worldwide, but making progress can be hindered by small numbers. That's where Our Future Health comes in. Read more about how this rich dataset is helping change the outlook for people with rare diseases: https://t.ly/TdkjX

The rare disease landscape can be complex to navigate – that's why we've collaborated with @rdrukhub.bsky.social to launch Raremap. It's a searchable directory of rare disease organisations so you can find out who does what and how to connect. Visit Raremap now: https://t.ly/nY3Rz

12 childhood cancers. 12 workshops. 24 months. We've just hosted the final Paediatric Therapeutic Development Workshop – a major milestone towards new treatment options for childhood cancers with the greatest unmet need. Read more: https://t.ly/SO81e

We're pleased to announce that over 30 recordings from #LATSS2026 are now available. If you weren't able to attend, or would like to revisit any of the sessions, you can explore them at your leisure on our YouTube channel: https://t.ly/OygJ3

Between 60–70% of medulloblastoma patients survive, but many face long-term side effects. For the highest-risk groups, survival is below 10%. Our workshop identified new treatment approaches to help address these urgent unmet needs for children. 🔗 Read more: t.ly/g5-qs

The first edition of the Global AMR Innovators Conference left a lasting impression. #GAMRIC2026 is coming to Lisbon in September – find out more and register now: gamric.org/

Our new partnership with University of Birmingham will see us developing a new targeted antibody for autoimmune diseases with our B-SMArT platform. An exciting step forward in finding safer, more targeted treatment options for patients.

At the LifeArc Translational Science Summit, our CEO Sam Barrell reflected on the importance of bringing together the translational community and why the UK is so well-placed to advance treatments for people living with rare diseases. #LATSS2026

Could we fix some disorders of the immune system by editing a patient's own cells? We're supporting a new study to treat CTLA-4 insufficiency using gene editing technology. Dr Thomas Fox, Principal Investigator for the trial, tells us more. Read more: t.ly/Wl7wL

We’re really pleased to welcome the Rare Therapies Launch Pad (RTLP) into LifeArc. RTLP has built a collaborative community focused on a shared challenge: how to turn advances in genetics into treatments that can reach individual patients.

We’re sponsoring National Patient Data Day 2026, led by @usemydata.bsky.social. Join webinars tomorrow to celebrate the use of patient data and discuss how to ensure that health data is used to save lives and improve outcomes for all. Register now: https://bit.ly/3Rkuvny #NPaDD2026

Drug-resistant infections threaten decades of medical progress. As the crisis worsens, we've formed partnerships to support innovators, remove barriers and help new tests and treatments reach patients sooner. 🔗Learn more about our partnerships: https://t.ly/1wlAB #AMR

We're looking back on footage from an inspiring day for insight, conversation and collaboration among the life sciences community at #LATSS2026. Full session recordings will be available soon – but here are some highlights from the day!

How do early-stage ideas become real drug discovery programmes for childhood cancer? Join this webinar from the C-Further team for insights from project leads, proposal tips and a look at how research is progressed. 🔗 Register here: https://t.ly/A85EN

People with lived experience bring unique and valuable knowledge to the research process. That's why we put the MND community at the heart of our funding call for drug repurposing projects. #GlobalMNDAwarenessDay

New target product profiles from the Cystic Fibrosis AMR Syndicate set out what future phage therapies for CF lung infections should look like, with patients at the heart. Download the TPPs: https://t.ly/JDJZW

Where there’s a common vision, there’s an opportunity for collaboration. The @ukdri.ac.uk shares our ambition to improve tests, treatments and ultimately find cures for people living with motor neuron disease and rare dementias. Learn more: https://t.ly/snVaa #PartnerForChange

Rhabdomyosarcoma is a rare, aggressive childhood cancer, with just 20–30% survival in cases where the cancer has spread. Our Paediatric Therapeutic Development Workshop identified 6 potential new treatment approaches. 🔗Findings now published in the British Journal of Cancer: t.ly/x-ubo

Could dogs help detect lung infections earlier for people with cystic fibrosis? That's what Jodie the Labrador is trained to do. If dogs can reliably detect infections in CF patients, if could mean earlier diagnosis, less intensive treatment and less lung damage. #CFWeek

We help partners navigate the clinical development journey of innovative new medical devices and diagnostics to support patient care. Learn more about the device and diagnostics studies we're supporting here: http://bit.ly/47Jq7Em

We’re delighted to feature in the new book Monarchy and Democracy: A History of Leadership, launched yesterday in the grounds of Westminster Abbey. The book celebrates the last 100 years of British leadership, with LifeArc illustrating the contribution of the life sciences sector.

Lung infections can still cause damage in cystic fibrosis, even when people feel healthier and cough up less sputum. Precision-CF is working to improve how infections are detected and understood, including through a wider range of sample types. #CFWeek

Health data can be transformative. For rare conditions, every data point matters. By partnering with @ourfuturehealthuk.bsky.social, we're turning high-quality data into insights that could speed up diagnosis and enable better trials. 🎥Learn more: https://t.ly/KPQA4 #PartnerForChange

Our LifeArc–Kidney Research UK Centre for Rare Kidney Diseases has created a children's book to help those living with these conditions feel seen and understood. Told in rhyme, 'See Me' sheds light on the often invisible challenges of kidney disease. 📚 Order now: t.ly/b4ksx

Last year, we selected 4 research projects for our Motor Neuron Disease (MND) Drug Repurposing Programme. Collaborating to overcome the scientific and translational challenges of drug repurposing, they aim to fast-track new treatments for MND. 🔗 t.ly/FVS6b

CognoMND is a simple digital tool that could allow people with motor neuron disease to be assessed for cognitive and behavioural changes in their own time, from the comfort of their homes. This could support earlier detection of changes and better care management. 🔗Learn more: https://t.ly/m_T4O

Our COO, Karen Skinner, wrote the foreword to the latest edition of Drug Discovery and Development by Pharma Press. She shares a timely perspective on the changing dynamics of the field and how to turn innovation into real-world impact. Read it here: https://t.ly/b8Kx3